Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Market Cap: US$132.3m

Tenaya Therapeutics Past Earnings Performance

Past criteria checks 0/6

Tenaya Therapeutics's earnings have been declining at an average annual rate of -26.9%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-26.9%

Earnings growth rate

81.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-104.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Sep 18
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Jun 04
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Mar 07
Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

Revenue & Expenses Breakdown

How Tenaya Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:TNYA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1173291
30 Jun 240-1213394
31 Mar 240-1253497
31 Dec 230-1243398
30 Sep 230-12833101
30 Jun 230-12933102
31 Mar 230-1243296
31 Dec 220-1243195
30 Sep 220-1162790
30 Jun 220-1042579
31 Mar 220-912269
31 Dec 210-731854
30 Sep 210-571542
30 Jun 210-491237
31 Mar 210-42933
31 Dec 200-38831

Quality Earnings: TNYA is currently unprofitable.

Growing Profit Margin: TNYA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TNYA is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.

Accelerating Growth: Unable to compare TNYA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TNYA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TNYA has a negative Return on Equity (-104.11%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tenaya Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Yevgeniya LivshitsChardan Capital Markets, LLC
Emanuela BranchettiH.C. Wainwright & Co.